Bortezomib
Acute Myeloblastic Leukemia Without Maturation
Explore 5 assets in Acute Myeloblastic Leukemia Without Maturation →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01127009CT.gov Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00666588CT.gov Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00383474CT.gov Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | — | Completed | — | — | — |
NCT00103272CT.gov 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloblastic Leukemia Without Maturation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bortezomib (this asset) | Fred Hutchinson Cancer Center | P2 | BB · 69 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | Northwestern University | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P3 | BBB |
| Mitoxantrone | Stanford University | P2 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the Acute Myeloblastic Leukemia Without Maturation cohort
Other indications for Bortezomib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BB · 71 |
| Waldenstrom Macroglobulinemia | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bortezomib in Acute Myeloblastic Leukemia Without Maturation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bortezomib-acute-myeloblastic-leukemia-without-maturation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →